Bausch + Lomb wins FDA clearance for Bi-Blade+ vitrectomy cutter

Bausch + Lomb Corporation +0.54% Pre
Bausch Health Companies Inc. -0.70% Pre

Bausch + Lomb Corporation

BLCO

16.71

16.71

+0.54%

0.00% Pre

Bausch Health Companies Inc.

BHC

5.68

5.68

-0.70%

0.00% Pre
  • FDA granted 510(k) clearance for Bausch + Lomb Bi-Blade+ dual-port vitrectomy cutter.
  • Agency also cleared Adaptive Fluidics advanced update for Stellaris Elite Vision Enhancement System.
  • Clearances expand Stellaris Elite surgical platform options for vitreoretinal procedures.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch + Lomb Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260408564994) on April 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.